US/UK/Canada

Share

About Us

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit professional organization with more than 2,700 members from over 45 countries dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy. For more information, visit www.ishlt.org.

Pick a time period -
Tags ( Active)

Hearts from Donation after Circulatory Death (DCD) Could Potentially Increase Transplants by 15 Percent

Study shows DCD hearts are a viable option for transplantationMONTREAL, April 25, 2013 – The results of a pre-clinical study show the viability of using hearts from donation after circulatory (or cardiac) Death (DCD) will be revealed today at the International Society for Heart and Lung Transplantation (ISHLT)  33rd Annual Meeting and Scientific Sessions in Montreal, Canada. The study focused on investigating the impact of varying periods of warm ischemia (is-KEE-mee-uh) (WI), cardiac function and evaluating pharmacological strategies to limit ischemic injury to the heart.

Sickest Children Not Benefiting from Recent Advances in Heart Transplant Therapy

Research indicates an overall decrease in pediatric waitlist mortality by 44 percentMONTREAL, April 25, 2013 – The latest research on children awaiting heart transplant will be presented today at the International Society for Heart and Lung Transplantation (ISHLT)  33rd Annual Meeting and Scientific Sessions in Montreal, Canada. The study set out to determine if waitlist survival has improved for children (under the age of 18) in the era of greater pediatric ventricular assist device (VAD) utilization using data from the Organ Procurement and Transplant Network (OPTN) (

Post Approval Study Confirms Clinical Trial Results for HeartMate II® in Destination Therapy

Results presented today at the International Society for Heart and Lung TransplantationMONTREAL, April 25, 2013 – Today, researchers will reveal the latest findings on a post-approval study for destination therapy (DT) at the International Society for Heart and Lung Transplantation (ISHLT)  33rd Annual Meeting and Scientific Sessions in Montreal, Canada. The study focused on comparing commercial results to the multicenter clinical trial conducted from 2005-2010 using the HeartMate II® Left Ventricular Assist Device (LVAD). Results in a commercial patient care setting

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media